Lanean...
Nonglycemic effects of dipeptidyl peptidase-4 inhibitors
The review considers the major nonglycemic effects of dipeptidyl peptidase-4 inhibitors commonly used in diabetological practice, by using as an example sitagliptin, the first and most investigated representative of this class.
Gorde:
| Egile Nagusiak: | , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Russo |
| Argitaratua: |
"Consilium Medicum" Publishing house
2013-01-01
|
| Saila: | Терапевтический архив |
| Gaiak: | |
| Sarrera elektronikoa: | https://ter-arkhiv.ru/0040-3660/article/view/31226 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|